Plasmabast Responses Provide a Signature for Lupus Disease Activity

The investigators also explain that, “While our study focused on SLE, our approach should be applicable to other clinically and genetically complex autoimmune diseases, such as rheumatoid arthritis, inflammatory bowel disease or inflammatory myopathies, where even approved therapies fail to induce remission in a significant number of patients. Future challenges include establishing the value of this approach to predict responses to targeted therapies and reducing the time to stratification.”

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

Reference

1. Banchereau R, Hong S, Cantarel B, et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. 2016 Jun 2;165(6):1548–1550. doi: 10.1016/j.cell.2016.05.057.